Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Dietary fiber has received considerable attention in both the popular press and the scientific literature. Fiber is a complex mixture of substances, and research on its effects is difficult to interpret. Dietary fiber has significant gastrointestinal effects, and it is a mainstay of treatment for constipation and hemorrhoids. Insoluble fiber, such as wheat bran, is most effective for treatment of these conditions. Increased intake of soluble dietary fiber appears to benefit patients with diabetes mellitus and hyperlipidemia. High-fiber, low-fat diets have been recommended by a variety of authorities to decrease the incidence of heart disease and certain types of cancer. Any increase in dietary fiber intake should be accompanied by an increase in water intake.
 ...
PMID:The clinical uses of dietary fiber. 784 38

Insulin resistance and hyperinsulinemia are characteristic features not only of obesity and NIDDM, but are associated with the development of hypertension, hyperlipidemia, and atherosclerosis. DeFronzo et al has used the analogy that insulin resistance can be viewed as a large iceberg submerged just below the water. The physician recognizes only the tips of the iceberg--obesity, diabetes, hypertension, hypertriglyceridemia and low-HDL cholesterol, and atherosclerosis--which protrude above the surface, while the complete insulin-resistance syndrome may be missed. With the recognition that insulin resistance consists of a cluster of nutritional causes and biochemical abnormalities, it is important for the various subspecialties to work together closely to define the mechanism(s) responsible for the defects in insulin-mediated glucose metabolism and to discover effective strategies for prevention and treatment.
 ...
PMID:Diabesity: the deadly pentad disease. 785 Dec 30

Epidemiological data indicate that omega-3 fatty acids protect from cardiovascular diseases and hyperlipidemia. Cold water fish is the major recognized source of omega-3 fatty acids but fish is not a staple food in many countries. Since terrestrial green plants may also represent a source of omega-3 fatty acids we tested the hypothesis that platelet rich plasma and milk from cows feeding exclusively on green grass contains more omega-3 fatty acids than milk from cows fed conserved grass. The relative concentrations of linolenic acid (18:3) and eicosapentaenoic acid (20:5) and the ratio of eicosapentaenoic acid to arachidonic acid (20:4) which is critical for the formation of omega-3 derived eicosanoids were significantly higher in milk from grass fed cows. Similar changes were seen in the fatty acid composition of platelets. Half a liter of milk from grass-fed cows provides approximately 191 mg 18:3 and 14 mg 20:5. In this regard milk from grass fed cows may be nutritionally superior to milk from cows eating conserved grass.
 ...
PMID:Increased concentrations of omega-3 fatty acids in milk and platelet rich plasma of grass-fed cows. 790 66

The effects of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the hyperlipidemia associated with nephrosis were studied. Nephrotic rats, induced by a single intraperitoneal injection of puromycin aminonucleoside (100 mg/kg body weight), had significantly higher plasma triglyceride (TG), total cholesterol and apoprotein (apo) B concentrations than controls. Fluvastatin was administrated as a 0.01% solution in drinking water for 14 days to either normal control or nephrotic rats. Concentrations of TG and apo B in plasma, and very low-density lipoprotein (VLDL) in nephrosis were completely normalized by the treatment with fluvastatin, but concentrations of cholesterol in plasma and each lipoprotein fraction were not altered by the treatment. The ratio of apo E to C in VLDL was significantly decreased in nephrotic rats, but the fluvastatin treatment increased this ratio. TG secretion rate estimated by the Triton WR1339 method was significantly increased in nephrotic rats, but was normalized by fluvastatin. Percent composition of TG in newly secreted VLDL particles in post-Triton plasma was not decreased by fluvastatin treatment, suggesting that the number of newly secreted VLDL particles was reduced by the treatment. Postheparin plasma lipolytic activities were not affected by the fluvastatin treatment. These results demonstrate that fluvastatin can effectively ameliorate the high concentration of VLDL by suppressing the hepatic secretion in nephrotic rats, and suggest that an inhibition of cholesterol biosynthesis suppresses VLDL secretion from the liver.
 ...
PMID:Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats. 807 13

The challenge of achieving health for all is enormous in the face of 500,000 maternal deaths a year; the fact that 2.9 billion people lack clean water and sanitation; the AIDS epidemic and malaria prevalence; substance abuse; population aging; runaway urbanization; environmental degradation; and violent human conflicts. To develop new ways of thinking and approaches, programs initiated by the Health Foundation of the Rogosin institute of New York entitled Problem-Solving for Better Health. The basic concept was that available limited resources (preventive, therapeutic, information, talent, and community) are seldom fully utilized, rather than are often wasted. The program involves attendance of a workshop lasting 3-5 days by 60 health professionals. The problem-solving strategies are discussed in large groups with a handbook for supporting presentations. Community involvement and international collaboration are stressed, and follow-up site visits take place after 6 months. The Health Foundation's INFO-MED computer program and interactive information centers provide up-to-date information for professionals working on health problems. In China, 54 professionals collaborated to solve health problems. In 1992, progress reports for 21 projects dealt with anxiety, violent behavior, attention-deficit disorders, hyperlipidemia, and wound healing. In Brazil, 53 health professionals were enrolled in 1990 and prepared some 50 solutions to problems, including patterns of violence among young males in Sao Paulo and nutritional deficiencies in slums. Six projects were implemented with 36 under development. In Ghana, 65 professionals devised solutions to problems in 1991, 12 projects are under way, and 1 on hearing problems in school children is ready for national implementation. In the US, a team from the University of Illinois Medical School launched a program in 1992 on geriatric, pediatric, and women's health issues. In Guyana, 70 professionals participated in a workshop in 1992 to strengthen community-based programs. In Nigeria, also in 1992, 78 participants prepared protocols on family planning, guinea-worm eradication, and environmental health.
 ...
PMID:Problem-solving for better health. 814 91

The systemic complications of nephrotic syndrome are responsible for much of the morbidity and mortality seen with this condition. This review discusses the causes for the hypoalbuminemia and the associated metabolic abnormalities of the nephrotic syndrome. No unifying hypothesis exists for the induction, maintenance, and resolution of nephrotic edema. In view of the wide spectrum of renal diseases leading to the nephrotic syndrome, more than a single mechanism may be responsible for the renal salt retention in these diverse conditions. Although hypoalbuminemia may be important, especially when plasma oncotic pressure is very low (serum albumin < 1.5 to 2.0 g/dL), primary impairment of salt and water excretion by the nephrotic kidney appears to be a major factor in pathogenesis of the edema. However, the decreased serum albumin and/or oncotic pressure seen with nephrotic syndrome is a major contributing factor to the development of the hyperlipidemia of nephrotic syndrome. Patients with unremitting nephrotic syndrome should be considered for combined dietary and lipid-lowering drug therapy. Urinary losses of binding proteins lead to the observed abnormalities in the endocrine system and in trace metals, and urinary losses of coagulation factors contribute to the hypercoagulable state. At present, selective renal venography is recommended when the suspicion of renal vein thrombosis is justified by clinical presentation. The impact on renal function caused by treating asymptomatic chronic renal vein thrombosis is undetermined, but anticoagulation for chronic renal vein thrombosis is associated with relatively few complications.
 ...
PMID:Extrarenal complications of the nephrotic syndrome. 815 83

Streptozotocin-diabetic and non-diabetic rats were given various concentrations of vanadyl sulphate in drinking water for one year. It was found that vanadyl sulphate caused significant decreases in body weight gain and plasma insulin level in non-diabetic rats, but did not significantly alter fluid and food intakes or plasma levels of glucose, triglycerides, or cholesterol. In diabetic animals, vanadyl treatment significantly alleviated or prevented the occurrence of hyperglycaemia, hypoinsulinaemia, hyperphagia, polydipsia, hyperlipidaemia, or cataract formation, but the slower body weight gain was not improved. There were gradual decreases in the intake of the compound required to correct hyperglycaemia in the values of ED50 with age of the rats. The beneficial effects of vanadyl treatment persisted 16 weeks following the withdrawal of the compound. It is concluded that vanadyl sulphate is an effective agent for chronic therapy of streptozotocin-induced diabetes in rats, and its prolonged use does not lead to the development of tolerance.
 ...
PMID:One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate. 819 Jun 97

This study was undertaken to determine the role of angiotensin II (AII) in the development of glomerulosclerosis, using an AII receptor antagonist in an animal model of hyperlipidemia. Hyperlipidemic Imai rats were employed because they spontaneously develop glomerulosclerosis; this is especially true in males. Group 1 (n = 5) received no specific therapy. Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age. Group 3 (n = 5) and group 4 (n = 6) were treated with the AII receptor antagonist DuP 753 at a respective dosage of 15 mg/l (low-dose DuP) and 150 mg/l (high-dose DuP) in drinking water. Body weight, blood pressure, urinary protein, serum albumin, cholesterol, BUN and serum creatinine were measured and compared among the groups from 12 to 24 weeks of age. Enalapril and high-dose DuP were almost equally effective in controlling systemic hypertension. Each treatment significantly reduced proteinuria (172 +/- 112 and 152 +/- 72 mg/kg/day at 24 weeks) as compared with that in the controls (421 +/- 147 mg/kg/day; p < 0.05 and p < 0.01, respectively). Hypercholesterolemia also decreased (82 +/- 4 and 89 +/- 6 mg/dl) as compared with that of the controls (141 +/- 48 mg/dl; both p < 0.05). Glomerulosclerosis index (SI) was significantly higher in the untreated control rats (55 +/- 26) than in the enalapril-treated rats (2 +/- 3; p < 0.005) and the high-dose-DuP-treated rats (6 +/- 6, p < 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. 828 94

Total body fat and anthropometric assessments of fat distribution were examined in 23 lean and obese rhesus monkeys (Macaca mulatta). In addition, the relationships of central obesity to hyperinsulinemia, insulin resistance, glucose intolerance and hyperlipidemia were studied. Total body fat (as determined by the tritiated water dilution method), plasma glucose, insulin, lipoproteins (triglyceride, cholesterol and HDL- and LDL-cholesterol) and free fatty acids (FFA), and glucose disappearance rate (KG) and peripheral insulin-stimulated glucose uptake (M) were obtained. Results showed that abdominal circumference was the best predictor of body fat (r = 0.90; P < 0.001). There were strong linear relationships between abdominal circumference and plasma insulin (r = 0.66), glucose tolerance (r = -0.53), and M rate (r = -0.59) (all P < 0.05) but not to plasma glucose, lipoprotein fractions, or free fatty acids. When the subjects were grouped according to degree of obesity and insulin resistance (lean normals, obese insulin sensitive, and obese insulin resistant), the obese resistant monkeys had significantly higher plasma insulin levels, lower glucose tolerance, and significantly higher plasma triglyceride levels. We conclude that the spontaneously obese rhesus monkey is an excellent model of central obesity. Furthermore, in this model upper body obesity appears to be facilitative in the development of hyperinsulinemia, glucose intolerance and hypertriglyceridemia but does not appear to be causally related. In the rhesus monkey and in humans as well, we propose that the link between central obesity and these metabolic abnormalities may be peripheral insulin resistance.
 ...
PMID:Central obesity in rhesus monkeys: association with hyperinsulinemia, insulin resistance and hypertriglyceridemia? 838 42

Thiazide diuretics have been the mainstay of antihypertensive therapy for over 30 years. Their precise mechanism of antihypertensive action is still incompletely understood. They reduce arterial pressure initially through a fall in plasma volume and cardiac output. However, with chronic administration cardiac output tends to return toward pretreatment levels, suggesting that the long-term pressure reduction is mediated through a reduction in vascular resistance. Although multiple lines of evidence suggest that salt and water loss is an essential part of the mechanism, at least in some cases an indirect vasodilator effect may play a role as well. The antihypertensive efficacy of diuretics is proven; they are at least as effective as other classes of antihypertensive drugs. They have been shown to protect against stroke, but not against mortality from myocardial infarction. There is some concern about the metabolic side effects, such as hypokalemia, hyperglycemia, and hyperlipidemia. In order to minimize these side effects the lowest effective dose should be used. Diuretics are likely to remain first-line antihypertensive agents, but they should be considered as one of several possible choices for the initial therapy among other classes, such as beta-blockers, ACE inhibitors, or calcium entry blockers.
 ...
PMID:The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years. 843 77


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>